Latest news with #FTO11
Mint
21-07-2025
- Business
- Mint
Stocks to watch: RIL, HDFC Bank, Eternal, JSW Steel, Jio Financial among shares in focus today
Shares of Eternal, IDBI Bank, UltraTech Cement, PNB Housing Finance will remain in focus as companies will declare Q1 results today. Reliance Industries Ltd (RIL) kicked off FY26 on a strong note, reporting a 76% year-on-year increase in consolidated net profit to ₹ 26,994 crore. The bank posted a robust performance in the June quarter, with Net Interest Income increasing by 10.6% year-on-year to ₹ 21,635 crore, while net profit grew 15.4% YoY to ₹ 12,768 crore. India's largest private bank reported a robust performance for the June quarter, with its Net Interest Income increasing by 5.4% year-on-year to ₹ 31,438 crore. Jio Financial Services Limited (JFSL) and Allianz Group, via its fully owned subsidiary Allianz Europe B.V., have signed a binding agreement to establish a 50:50 domestic reinsurance joint venture aimed at catering to India's fast-growing and evolving insurance market. Yes Bank posted a 59% year-on-year increase in its standalone net profit for Q1FY26, rising to ₹ 801 crore from ₹ 502 crore in the same quarter last year. The company's net profit jumped to ₹ 2,184 crore, marking a sharp rise from ₹ 845 crore in the corresponding quarter a year ago. The private sector lender reported a weak performance for the June quarter, with Net Interest Income falling 13% year-on-year to ₹ 1,480.6 crore and net profit dropping sharply by 46% to ₹ 200 crore. The company posted an impressive performance in Q1 FY26, with net profit surging 75.5% year-on-year to ₹ 324.3 crore and revenue rising 19.4% to ₹ 3,352.5 crore. Warburg Pincus (through Currant Sea Investments B.V) has secured approval from the Reserve Bank of India (RBI) to proceed with its planned 9.99% stake investment in IDFC First Bank. Punjab and Sind Bank posted a 48% rise in net profit to ₹ 269 crore for the first quarter. The USFDA has issued a Form 483 containing seven observations to Dr. Reddy's Laboratories after conducting a GMP and Pre-Approval Inspection at its FTO 11 formulations plant in Srikakulam, Andhra Pradesh. Disclaimer: This story is for educational purposes only. The views and recommendations above are those of individual analysts or broking companies, not Mint. We advise investors to check with certified experts before making any investment decisions.
&w=3840&q=100)
Business Standard
20-07-2025
- Business
- Business Standard
Dr Reddy's gets 7 USFDA observations after Srikakulam plant inspection
A Form 483 is issued by the US health regulator when inspectors identify conditions that may violate the Food, Drug, and Cosmetic (FD&C) Act or relevant guidelines New Delhi Hyderabad-based pharmaceutical major Dr Reddy's Laboratories (DRL) has received a Form 483 with seven observations from the United States Food and Drug Administration (USFDA) in a recent inspection at its formulations manufacturing plant in Srikakulam, Andhra Pradesh, according to the exchange filing. The USFDA concluded the inspection of its FTO 11 facilities, the company stated in the filing. A Form 483 is issued by the US health regulator when inspectors identify conditions that may violate the Food, Drug, and Cosmetic (FD&C) Act or relevant guidelines. 'We have been issued a Form 483 with seven observations, which we will address within the stipulated timeline,' it added. Dr Reddy's Laboratories reported a 22 per cent year-on-year rise in consolidated net profit for the fourth quarter of financial year 2025, reaching ₹1,593.9 crore. The company has also announced a final dividend of ₹8 per equity share for FY 2024-25. The company's first-quarter results for FY26 are scheduled to be released on July 23.
